1. Looking Beyond Glucose Control: Multifactorial Management of Type 2 Diabetes

3. Introduction/Overview

4. Tracking the Global Obesity Epidemic

5. Obesity and T2DM as Risk Factors for a Range of Comorbid Conditions[a,b]

6. The Obesogenic Environment

7. Mechanisms of Obesity-Associated T2DM

8. Weight Effects of Glucose-Lowering Therapies

9. Close Linkage Between T2DM and HF

10. Diabetes Prevention Program: Moderate Weight Loss Associated With Reduced Incidence of T2D

11. Look AHEAD: Intensive Lifestyle Intervention, Focused on Weight Loss, Did Not Improve CV Risk in T2DM

12. Look AHEAD Results: No Significant Improvement in CV Outcomes, but Other Benefits Were Observed

13. Prevention of T2DM With Bariatric Surgery vs Control: SOS Trial

14. SOS T2DM Remission Results: Some Reduction in Remission Over Time

15. GLP-1 RAs and BP Reduction

16. GLP-1 RAs and Lipids Reduction

17. GLP-1 RAs: Approved or in Development

18. Glucose-Lowering Therapies and Attainment of HbA1c Goals

19. LEADER: Primary Outcome Results*

20. SUSTAIN-6 (Semaglutide): Primary Outcome Results

21. Liraglutide and NASH

22. Pooled Analysis of Weight Change Associated With GLP-1 RAs, DPP-4s, and SGLT2 Inhibitors

23. DURATION-8: Weight Change Results

24. SUSTAIN-7: Topline Results, HbA1c

25. SUSTAIN-7: Topline Results, Body Weight

26. Weight Loss Maintenance: Results From SCALE Maintenance Trial

27. Summary and Conclusions